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ABSTRACT OF THESIS 
A POPULATION-BASED ANALYSIS OF PATIENT AGE AND OTHER 
DISPARITIES IN THE TREATMENT OF OVARIAN CANCER IN CENTRAL 
APPALACHIA AND KENTUCKY 
Objectives: Adherence to National Comprehensive Cancer Network (NCCN) 
guidelines for ovarian cancer treatment improves patient outcomes. The aim of this 
study is to assess disparities associated with ovarian cancer treatment in the state of 
Kentucky and Central Appalachia. 
Methods: Patients diagnosed with ovarian cancer from 2007-2011 were extracted 
from administrative claims-linked Kentucky Cancer Registry data. NCCN compliance 
was defined by stage, grade, surgical procedure and chemotherapy. Selection criteria 
were carefully reviewed to ensure data quality and accuracy. Descriptive analysis, 
logistic regression, and Cox regression analyses were performed to examine factors 
associated with guidelines compliance and survival. 
Results: Most women were age 65 years or older (62.5%), had high grade 
(65.9%) and advanced stage (61.0%) ovarian cancer. Two-thirds of cases (65.9%) 
received NCCN-recommended treatment for ovarian cancer. The hazard ratio (HR) of 
death for women who did not receive NCCN-compliant care was 62% higher compared 
to the women who did receive NCCN compliant treatment (HR 1.62, 95% CI 1.11-2.35). 
Results from the logistic regression showed that NCCN-compliant treatment was more 
likely for: women age 65-74 years compared to age 20-49 (OR=3.32, 95% CI=1.32-
8.32), late stage compared to early stage cancers (OR 0.32, 95% CI 0.20-0.53), receipt of 
care at tertiary hospitals (OR=1.92, 95% CI=1.10-3.34), and privately insured compared 
to Medicaid (OR=0.31, 95% CI=0.13-0.77) or Medicare (OR=0.31, 95% CI=0.15-0.66). 
Conclusions: When the treatment of ovarian cancer did not follow NCCN-
recommendations, patients had a significantly higher risk of death. Women were less likely 
to receive NCCN-compliant care if they were of younger age (20-49 years), had early stage 
disease, were not privately insured, or had care provided at a non-tertiary hospital. 
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HIGHLIGHTS 
● There is a higher risk of death if ovarian cancer treatment is not NCCN-compliant
● Younger women are more likely to receive non-compliant care than older women
● Non-compliance was also more common for early stage disease and non-private
insurance
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CHAPTER 1. INTRODUCTION 
Ovarian cancer is one of the more lethal gynecologic cancers as it regularly 
presents in advanced stage (1) and many women do not receive expert-recommended care 
(2). Until progress is made with the early detection of ovarian cancer, it is important to 
understand the barriers preventing women from receiving NCCN-compliant treatment. 
The National Comprehensive Cancer Network (NCCN) publishes detailed guidelines for 
the treatment of ovarian cancer which include comprehensive surgical staging for early 
stage cancers and aggressive surgical cytoreduction for advanced stage disease. With the 
exception of low grade early stage ovarian malignancies, platinum and taxane-based 
chemotherapy is recommended following surgery. Adherence to NCCN guidelines has 
been shown to improve patient outcomes (2). Unfortunately, as many as two-thirds of 
women with ovarian cancer are not referred to a gynecologic oncologist for their primary 
surgery (3) (4) and a similar fraction do not receive NCCN-compliant care (2). 
A number of factors have previously been associated with non-compliant 
treatment according to NCCN guidelines. These include hospital and surgeon case 
volume (2), treatment at NCI Comprehensive Cancer Center facilities (5), cancer stage 
(6), geographic proximity to the hospital (7), race (8), and socioeconomic status (8). Even 
though the median age at diagnosis for ovarian cancer is 63 years, 55% of women 
diagnosed with invasive ovarian cancer are younger than 65 years of age (9); therefore, 
women of all ages should be included in population-based evaluations. We should also 
consider whether non-compliant treatment is an intentional act of commission. A single 
institutional report from the University of Alabama at Birmingham noted that common 
reasons for non-compliance were intentional and related to: chemotherapy toxicity, 
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disease progression, patient refusal, and co-morbidities preventing recommended surgery 
or chemotherapy (10). An analysis of guideline concordance for colorectal cancer in the 
Appalachian region of Kentucky demonstrated that non-compliance was associated with 
chronic medical conditions, including myocardial infarction and congestive heart failure; 
and surgical non-compliance was associated with low volume centers and hospitals that 
were not designated by the Commission on Cancer (COC) (11). 
Our study objective was to perform a detailed analysis of treatment disparities for 
ovarian cancer in the state of Kentucky and Central Appalachia based on published 
NCCN guidelines. 
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CHAPTER 2. MATERIALS AND METHODS 
This is a retrospective, population-based investigation of women diagnosed with 
ovarian cancer while living in the state of Kentucky from January 1, 2007 to December 
31, 2011. Permission to perform the investigation was granted by the University of 
Kentucky Institutional Review Board as an exempt protocol. 
Ovary cancer cases were selected based on ICD-O-3 site codes C569, and 
extracted from the Kentucky Cancer Registry (KCR) database. The KCR database was 
linked to insurance claim databases in the state of Kentucky including Medicare, 
Medicaid, and private insurers. This unique merging of clinical data eliminated patient 
age constraints seen when cancer registries are coupled to Medicare (patients age 65 
years and older). In addition, use of both private and non-private insurers allow for a 
more complete review of medical comorbidities and insurance-related variables. 
Patient eligibility included an ovarian cancer diagnosis in the state of Kentucky, 
age over 20 years, and a first diagnosis of an invasive cancer. To ensure complete and 
accurate treatment information, we included only patients with continuous insurance 
enrollment in the first year of cancer diagnosis (month of cancer diagnosis and 12 months 
following) or till the month of death in the first year. Borderline and non-epithelial 
ovarian malignancies were excluded from this study. There were 1,450 cases identified 
with a diagnosis of ovarian cancer during the study period. Three hundred and sixty-one 
cases were excluded, as they had insufficient details to determine surgical procedures 
performed. Twenty were excluded due to age under 20 years, and 179 were excluded as 
ovarian cancer was not their first cancer diagnosis. An additional 68 cases were excluded 
due to non-epithelial histology. Since we defined NCCN-compliance to include 
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chemotherapy information captured from KCR linked claims files, 322 cases were 
excluded as they did not have at least 13 months of continuous claims data. Thus, there 
were a total of 413 cases for the complete analysis. 
The primary outcome investigated was compliance with NCCN 
recommendations for ovarian cancer treatment. Chemotherapy and surgical guideline 
compliance were grouped together to form a single bivariate value for compliance. For 
stages IIIB and below, adherence required a minimum performance of oophorectomy and 
lymphadenectomy, whereas stages IIIC and above required a minimum of oophorectomy 
and omentectomy, and allowed for more extensive cytoreductive procedures. Guideline 
compliance required chemotherapy administration for all study cases with the exception 
of stage IA and stage IB grade 1 cancers. Surgical information was captured using KCR 
data, and chemotherapy information was identified by claims data linked to KCR data. 
Hospitals were classified as high volume (>15 cases per year) or low volume 
(<15 cases per year) based on the number of ovarian cancer cases performed. Academic 
hospitals were defined to be tertiary hospitals. The patient-specific variables analyzed 
were: age, race, insurance type, Appalachian residence versus metropolitan status, 
educational level (percentage with high school education at county level), income level 
(percentage below the poverty level at county level), insurance type, treatment with 
neoadjuvant chemotherapy, and geographical distance to the closest tertiary hospital. We 
used the Great Circle Distance (GCD) method to calculate geographical distance, adapted 
North American Association of Central Cancer Registries (NAACCR)’s SAS application 
(GIS Resources. NAACCR https://www.naaccr.org/gis-resources/#GREATCIRCLE). 
Appalachian status was based on the definition from the Appalachia Regional 
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Commission (https://www.arc.gov/index.asp). The 2003 Rural-Urban Continuum Codes 
were used to define metro and non-metro status with values 1-3 as metro and 4-9 as non-
metro https://www.ers.usda.gov/data-products/rural-urban-continuum-codes/. The 
Charlson Comorbidity Index (CCI) was assigned based on KCR linked claims data from 
a time period spanning 12 months to one month prior to cancer diagnosis. The CCI 
variable was treated as unknown when 12 months of continuous claims coverage prior to 
the cancer diagnosis was unobtainable. Tumor-related variables included: cell type, stage, 
grade, number of lymph nodes examined, and tumor size. 
Descriptive analysis was conducted for all variables. Bivariate analyses with Chi-
Square tests were performed to examine the association between guideline compliance 
and other covariates. Multivariate logistic regression models were fitted to determine 
significant factors associated with the delivery of NCCN-compliant care. Kaplan-Meier 
plots and Log-Rank tests were conducted for survival analysis. A Cox regression analysis 
was performed to determine the survival effects of various covariates, including NCCN 
compliance. All analyses were done using SAS Statistical software version 9.4 (SAS 
Institute, Inc., Cary, NC). Statistical tests were two-sided with a p-value ≤ 0.05 used to 
identify statistical significance. 
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CHAPTER 3. RESULTS 
Two hundred and seventy-two women out of a total study population of 413 
(65.9%) received NCCN guideline compliant care. For the 141 women who did not 
receive guideline-compliant care, 87 (61.7%) did not receive the recommended 
chemotherapy, and 79 (56.0%) did not receive the appropriate surgery. 
The summary of demographic characteristics is shown in Table 1. The mean age 
of the study population was 65.5 years, and 62.3% of study subjects were 65 years or 
older. More than half of the cancers were diagnosed at an advanced stage (60.9%). The 
majority were also grade 3 or 4 malignancies (65.7%). Fewer than 10% of patients had a 
Charlson Comorbidity Index greater than 2. Only 39.1% of cases were treated at a tertiary 
hospital, while 58% were treated at high volume hospitals as defined by at least 15 
ovarian cancer cases per year. Medicare insured 65% of the women in this study. 
Although more women were treated in non-Appalachian metropolitan areas (44.7 %) than 
any other, 31.2% were still treated in rural Appalachia. 
3.1 NCCN Guideline Compliance 
The bivariate analysis between patient characteristics and NCCN-compliance are 
listed in Table 1. Women who received NCCN-adherent care were more likely to have 
late stage disease (stage III and stage IV), smaller size tumors (less than 10 cm), and 
treatment at a tertiary hospital. Women from non-Appalachian metropolitan areas were 
more likely (51.9%) to have private insurance carriers, whereas women from 
Appalachian rural areas were more likely to be covered by Medicaid. Patient income and 
education level were not associated with NCCN compliance or survival. The average 
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Great Circle Distance (GCD) to the closest academic hospital for all subjects was 62.9 
miles (±48.5 miles). The average GCD for non-compliant cases GCD was 59.8 miles 
(±45.3 miles) compared to NCCN-compliant cases of 64.5 miles (±50.1 miles). There 
was no statistical difference between these groups. 
The characteristics associated with NCCN guideline adherence on multivariate 
logistic regression are shown in Table 2. Women of age 65-74 years were significantly 
more likely to be guideline compliant compared to women age 20-49 years (OR 3.316, 
95% CI 1.322-8.320). Compared to stage IIIC and IV, treatment of earlier stage disease 
was less NCCN-compliant (OR 0.32, 95%CI 0.198-0.526). Patients treated at a tertiary 
hospital were also more likely to receive NCCN-adherent care (OR 1.921, 95%CI 1.104-
3.341). Compared to women who were privately insured, those insured by Medicaid (OR 
0.311, 95%CI 0.125-0.774) or Medicare (OR 0.312, 95%CI 0.148-0.659) were much less 
likely to be guideline compliant. 
3.2 Patient Survival 
The results from the Cox regression model are shown in Table 3. NCCN guideline 
compliant treatment was associated with significantly better survival (HR=1.615, 95%CI 
1.111-2.347) than non-compliant cases. In addition, women who lived in non-Appalachian 
metropolitan areas had better survival compared to women living in rural Appalachian 
areas (HR 0.698, 95%CI 0.491-0.990). Patient’s distance to closest tertiary hospital was 
marginally associated with survival (HR 1.003, 95%CI 1.000-1.006). As expected, overall 
survival was better for younger compared to older women, early compared to late stage 
diagnosis, and women with low compared to high CCI. 
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Table 1.  Characteristics of Patients with Ovarian Cancer by NCCN Guideline Adherence 
Status, 2007-2011 
Variables 
Total Guideline Non-Compliant 
Guideline 
Compliant P value 
N % N % N % 
Total 413 100.0 141 34.1 272 65.7 
Age 
20-49 46 11.1 20 43.5 26 56.5 0.121 
50-64 109 26.3 34 31.2 75 68.8 
65-74 163 39.4 48 29.5 115 70.6 
>75 95 22.9 39 41.1 56 59.0 
Race 
White and 
other 
402 97.1 138 34.3 264 65.7 0.756 
Black 11 2.7 3 27.3 8 72.7 
Stage 
I 114 27.5 47 41.2 67 58.8 0.000 
II 47 11.4 23 48.9 24 51.1 
III 166 40.1 37 22.3 129 77.7 
IV 86 20.8 34 39.5 52 60.5 
Grade 
1 23 5.6 9 39.1 14 60.9 0.097 
2 64 15.5 26 40.6 38 59.4 
3 165 39.9 52 31.5 113 68.5 
4 107 25.8 29 27.1 78 72.9 
Unknown 54 13.0 25 46.3 29 53.7 
Tumor Size 
<5 cm 78 18.8 23 29.5 55 70.5 0.030 
5-10 cm 100 24.2 24 24.0 76 76.0 
>10 cm 148 35.7 60 40.5 88 59.5 
Unknown 87 21.0 34 39.1 53 60.9 
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Table 1.  (continued) 
Charlson Comorbidity Index 
0 226 54.6 71 31.4 155 68.6 
0.216 
1 100 24.2 34 34.0 66 66.0 
2 20 4.8 9 45.0 11 55.0 
3 or greater 11 2.7 2 18.2 9 81.8 
Unknown 56 13.5 25 44.6 31 55.4 
Tertiary versus Non Tertiary Hospital 
Tertiary 
Hospital 162 39.1 46 28.4 116 71.6 
0.048 
Non Tertiary 
Hospital 251 60.6 95 37.9 156 62.2 
Hospital Volume of Ovary Cancer Cases per year 
> 15 
cases/year 240 58.0 74 30.8 166 69.2 0.095 
<15 cases/year 173 41.8 67 38.7 106 61.3 
Income Level 
Low 114 27.5 39 34.2 75 65.8 
0.873 
Moderate 103 24.9 33 32.0 70 68.0 
High 94 22.7 31 33.0 63 67.0 
Very High 102 24.6 38 37.3 64 62.8 
Insurance Type 
Not Insured 3 0.7 2 66.7 1 33.3 
0.068 
Private 
Insurance 106 25.6 26 24.5 80 75.5 
Medicaid 33 8.0 16 48.5 17 51.5 
Medicare 269 65.0 97 36.1 172 63.9 
Other Public 1 0.2 0 0.0 1 100.0 
Unknown 1 0.2 0 0.0 1 100.0 
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Table 1.  (continued) 
Appalachian Residence Metropolitan Status 
Appalachian 
Metro Area 18 4.3 2 11.1 16 88.9 
0.170 
Appalachian 
Rural Area 129 31.2 46 35.7 83 64.3 
Non 
Appalachian 
Metro Area 
185 44.7 62 33.5 123 66.5 
Non 
Appalachian 
Rural Area 
81 19.6 31 38.3 50 61.7 
Chemotherapy Adherence 
Chemothera
py Adherent 323 78.2 54 16.7 269 83.3 
<0.001 Chemothera
py Non 
Adherent 
90 21.8 87 96.7 3 3.3 
Surgery Adherence 
Surgery 
Adherence 334 80.9 62 18.6 272 81.4 
<0.001 
Surgery Non 
Adherence 79 19.1 79 100.0 0 0.0 
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Table 2.  Factors Associated with Guideline Compliance based on the Logistic 
Regression 
Variable OR* 95% C.I. P-value
Age Groups 
50-64 1.897 0.851 4.228 0.027 
65-74 3.316 1.322 8.320 
>75 1.730 0.661 4.528 
20-49 Ref 
Stage 
Stage IA IB with Grade 1 0.151 0.022 1.020 <0.001 
Stage IA-IIIB 0.323 0.198 0.526 
Stage IIIC-IV Ref 
Grade 
Grade 2 0.421 0.093 1.898 0.071 
Grade 3 0.548 0.128 2.351 
Grade 4 0.529 0.119 2.358 
Unknown 0.212 0.045 0.990 
Grade1 Ref 
Charlson Comorbidity Index 
1 1.188 0.675 2.090 0.171 
2 0.731 0.267 1.999 
3+ 3.803 0.710 20.356 
Unknown 0.544 0.263 1.128 
0 Ref 
Tertiary 
Tertiary Hospital 1.921 1.104 3.341 0.021 
Non Tertiary Hospital Ref 
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Table 2. (continued) 
Income Level 
Low 1.014 0.362 2.834 
0.956 
Moderate 1.000 0.339 2.955 
High 1.188 0.539 2.615 
Very High Ref 
  
Insurance Status 
Medicaid 0.311 0.125 0.774 
 
Medicare 0.312 0.148 0.659 0.003 
Private Insured Ref 
   
Appalachian Residence and Metropolitan Status 
Appalachian Metro Area 5.069 0.890 28.876  
Non Appalachian Metro Area 1.325 0.480 3.662 0.166 
Non Appalachian Rural Area 0.847 0.356 2.016  
Appalachian Rural Area Ref      
*OR, Odds Ratio 
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Table 3.  Factors Associated with Survival from the Cox Regression Model 
Variable 95% C.I. P-value
Age Groups 
50-64 1.732 1.028 2.919 0.043 
65-74 1.732 0.974 3.082 
>75 2.316 1.256 4.271 
20-49 Ref 
Stage 
Stage I 0.090 0.054 0.151 <0.001 
Stage II 0.185 0.108 0.315 
Stage III 0.653 0.480 0.888 
Stage IV Ref 
Grade 
Grade 0.325 
Grade 2 1.114 0.477 2.604 
Grade 3 1.329 0.599 2.946 
Grade 4 1.251 0.553 2.830 
Unknown 0.831 0.341 2.026 
Grade1 Ref 
Charlson Comorbidity Index 
1 1.101 0.794 1.528 0.323 
2 1.575 0.868 2.859 
3+ 2.458 1.200 5.033 
Unknown 1.506 0.970 2.339 
0 Ref 
Tertiary 
Tertiary Hospital 1.034 0.765 1.397 0.830 
Non Tertiary Hospital Ref 
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Table 3.  (continued) 
Insurance Status 
Medicaid 1.340 0.773 2.323 
0.510 Medicare 1.188 0.780 1.809 
Private Insured Ref 
  
Appalachian Residence and Metropolitan Status 
Appalachian Metro Area 0.876 0.440 1.742 
0.194 
Non Appalachian Metro Area 0.698 0.491 0.990 
Non Appalachian Rural Area 0.742 0.497 1.108 
Appalachian Rural Area Ref 
  
GCD to Closest Tertiary Hospital 1.003 1.000 1.006 0.094 
Guideline Adherence 
NCCN Guideline Non Adherent 1.615 1.111 2.347 
0.012 
NCCN Guideline Adherent Ref     
*HR, Hazard Ratio 
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Figure 1.  Kaplan Meier Plots for Ovarian Cancer Patient Survival by Compliance Status 
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DISCUSSION 
Ovarian cancer remains a significant cause of cancer death for women. One way 
to improve cancer outcomes is to ensure that women have access to expert-recommended 
care. Cancer incidence rates in Kentucky are among the highest in the United States, and 
the geographical region of Central Appalachia has numerous barriers that may limit 
access to expert medical care. Understanding the specific disparities is critical to 
improving ovarian cancer outcomes in this region. 
The age adjusted incidence for ovarian cancer in the state of Kentucky in 2013-
2014 was 10 cases per 100,000 people, similar to the national rate of 11.9 cases per 
100,000 people (12). The corresponding age-adjusted mortality rate is 6.8 per 100,000 in 
Kentucky versus 7.2 per 100,000 nationwide (12). Compliance rates for NCCN-
recommended treatment for ovarian cancer have not been previously reported for the 
state of Kentucky or Central Appalachia. 
In this investigation, the overall NCCN compliance rate for the treatment of 
ovarian cancer was 65%. As reported in other studies, women who received guideline-
compliant care had better overall survival. In our multivariate analysis, younger women 
(20-49 years) were significantly less likely to receive guideline recommended ovarian 
cancer treatment compared to age 65-74 years. Previous publications have reported that 
older women are at risk of receiving NCCN non-compliant care for ovarian cancer (7) 
(13) (14) (8) , but our findings are the first show this disparity in younger women. This is 
particularly poignant when considering the potential number of life-years at risk for 
young women diagnosed with cancer. When using Medicare-linked databases, 
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population-based reports are restricted to age 65 years or older (8). In our investigation, 
we were able to include all women age 20 years or older. 
We elected to analyze age as a categorical as opposed to a continuous variable. 
This is logical as expert organization guidelines directing management of adnexal masses 
vary for premenopausal versus postmenopausal women (15). Furthermore, age related 
comorbidities are likely to be a greater factor in elderly women, as opposed to those who 
have just gone through menopause. Consequently, utilizing three age strata (20-49, 65-
74, >75) considers age in relation to these key factors, as opposed to consideration of age 
as a continuous variable. The results of our survival analysis demonstrate that younger 
age is associated with better survival; which is an expected result. The results of our 
logistic regression, demonstrate that younger age is associated with inferior guideline 
compliance, which is unexpected. This may suggest that decision-making guidelines in 
the younger than 50 years age group are not satisfactory. 
Other publications have demonstrated low rates of NCCN guideline compliance 
for early stage cancers (6) (13). We also find that women with early stage ovarian cancer 
are less likely to receive NCCN-compliant care. As young women are more likely to have 
early stage disease (16), it is possible that stage and age are confounding factors in these 
analyses. Patients with early stage ovarian cancer are more likely to have appropriate 
staging and treatment when their initial surgery is performed by a gynecologic oncologist 
(17), so referral to a specialist is an important consideration. 
In our study, patients with private insurance were more likely to receive 
guideline-compliant treatment than those with Medicaid or Medicare. This relationship 
between insurance provider and quality of care in ovarian cancer has been previously 
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reported (14). It is not well understood why the type of insurance impacts the quality of 
treatment, though possible explanations include differences in physician reimbursement, 
cultural issues relating to access, or the possibility that insurance type may be a surrogate 
variable for socioeconomic status. It is important to note that in this investigation, patient 
education and income status were not associated with differences in NCCN-compliance 
or with overall survival. 
NCCN guideline compliance was higher when treatment was provided at a 
tertiary care facility. It is well known that for the treatment of ovarian cancer, high 
volume hospitals, and experienced surgeons provide more guideline-concordant care (2). 
In addition, a recent report demonstrated greater rates of concordance when care was 
provided at NCI-designated Comprehensive Cancer Centers (CCC), compared to both 
high and low volume hospitals that were not NCI-designated CCC hospitals (5). 
Other publications on ovarian cancer treatment have commented on disparities in 
guideline concordance based on socioeconomic status and race (18). No race disparate 
care was noted in our analysis, but the evaluation is limited by small numbers of African 
Americans in Central Appalachia (1.9%) and the state of Kentucky (7.9%). Insurance 
type may have served as a surrogate variable for socioeconomic status, as income levels 
are based upon census tract data in relationship to a subject’s zip code of residence, while 
Medicaid insurance status is linked to low income on an individual level. We did observe 
a survival difference favoring non-Appalachian metropolitan populations compared to 
rural Appalachian populations. It is not evident whether this is related to the quality of 
care or other factors. Increased cancer mortality for Appalachian populations is a 
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relationship previously accredited to several factors including, medical comorbidities and 
access to care (19). 
The literature is replete with guidelines and strategies for the preoperative 
evaluation of an ovarian mass; nevertheless, disparate cancer treatment remains 
commonplace. Many women are still not referred to a gynecologic oncologist for their 
initial ovarian cancer operation (17) (3). Ultrasound is available worldwide as a reliable 
and objective method to evaluate ovarian tumors (20) (21). Serial sonography further 
enhances ultrasound’s ability to differentiate benign from malignant ovarian tumors (22) 
(23). In addition, multivariate index assays are highly sensitive in detecting malignancy 
(24) (25) (26) (27) including early stage cancers (28), and can be combined with 
ultrasound to further stratify the likelihood of malignancy (29). These practical 
preoperative evaluation strategies should be considered for all women whose ovarian 
tumors are concerning enough to require surgery, regardless of cancer stage, patient age, 
location, or insurance provider. 
The authors acknowledge several study limitations. Claims data allowed us to 
determine whether or not chemotherapy was received, but we were unable to determine 
individual agents or number of cycles. We were also unable to determine the subspecialty 
or case volume of the primary surgeon, both of which have been associated with survival 
in other studies (14) (2). Lastly, our survival analysis did not include parameters related 
to the extent of primary cytoreduction, or parameters related to disease recurrence, 
including time to recurrence, and specific chemotherapy agents administered. 
Our study has the following strengths. Our team linked KCR data to the majority 
of insurance databases our state, thereby minimizing insurance provider related biases. 
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Such biases are potentially significant in regards to age (Medicare – age over 65), and in 
regards to socioeconomic status (public versus private insurance in relation to patient 
income level). Our study gave a thorough account of medical comorbidities, a significant 
confounding variable that impacts decisions related to surgery and chemotherapy. The 
requirement for 13 months of continuous claims data mandated the exclusion of a 
substantial number of cases, but enabled us to capitalize on features of our KCR-
insurance provider linked database. Lastly, we were able to use this comprehensive 
database to investigate patterns of care for ovarian cancer in Central Appalachia, an 
underserved and understudied region of the United States. 
The findings of this investigation reaffirm that ovarian cancer survival is highest 
when treatment is concordant with published NCCN guidelines. Women with early stage 
disease, non-private insurance, or treatment at non-tertiary care hospitals are more likely 
to receive non-compliant care. We also report that younger women with ovarian cancer 
are significantly less likely to receive NCCN compliant care. Continued patient and 
physician education is needed to ensure that available imaging and biomarker tests are 
routinely used to help identify high risk women for referral to an ovarian cancer 
specialist, regardless of cancer stage, location, insurance provider, or patient age.
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